Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 25, Issue 2, 2014, Pages 87-94

  Wagner, Monika ^a   Lavoie, Louis ^a   Goetghebeur, Mireille ^a  

^a LA SER Analytica BioMedCom   (Canada)

Author keywords

Clostridium difficile; Cost effectiveness; Fidaxomicin; Recurrence; Vancomycin

Indexed keywords

FIDAXOMICIN; VANCOMYCIN;

ARTICLE; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE MODEL; DISEASE SEVERITY; DRUG COST; ECONOMIC ASPECT; HEALTH CARE SYSTEM; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHYSICIAN; RECURRENT INFECTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84897128255     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2014/793532     Document Type: Article

References (39)

1. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009;30:57-66.
2. Bartlett JG. Narrative review: The new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64. (Pubitemid 351650356)
3. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9. (Pubitemid 41770165)
4. MacCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 2006;44:2147-52. (Pubitemid 43902167)
5. Morgan OW, Rodrigues B, Elston T, et al. Clinical severity of Clostridium difficile PCR ribotype 027: A case-case study. PLoS One 2008;3:e1812.
6. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037-42.
7. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007;102:2781-8. (Pubitemid 350179349)
8. Pillai DR, Longtin J, Low DE. Surveillance data on outbreaks of Clostridium difficile infection in Ontario, Canada, in 2008-2009. Clin Infect Dis 2010;50:1685-6.
9. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009;48:568-76.
10. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004;171:466-72. (Pubitemid 39179608)
11. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7. (Pubitemid 40720808)
12. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: A systematic review. J Hosp Infect 2010;74:309-18.
13. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137-40. (Pubitemid 34246541)
14. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009;15:1067-79.
15. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
16. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-98.
17. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:2386-8. (Pubitemid 30414372)
18. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-33. (Pubitemid 27096783)
19. Drekonja DM, Butler M, Macdonald R, et al. Comparative effectiveness of Clostridium difficile treatments: A systematic review. Ann Intern Med 2011;155:839-47.
20. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
21. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-9.
22. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: Meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012;55(Suppl 2):S93-103.
23. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;16:297-304.
24. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758-64. (Pubitemid 43363928)
25. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219-27. (Pubitemid 47596558)
26. Perras C, Tsakonas E, Ndegwa S. Vancomycin or metronidazole for treatment of Clostridium difficile infection: Clinical and economic analyses. Canadian Agency for Drugs and Technologies in Health 2011. 〈http://cadth.ca/en/ products/health-technology-assessment/publication/2775〉 (Accessed January 23, 2012).
27. Canadian Drug Expert Committee. Final CDEC recommendation. Fidaxomicin (Dificid). Canadian Agency for Drugs and Technologies in Health 2012 December 21. 〈www.cadth.ca/media/cdr/complete/cdr-complete-Dificid-December-21-12. pdf〉 (Accessed June 5, 2013).
28. Ontario Ministry of Health and Long-Term Care. Schedule of benefits for physician services. Consultations and visits. Ontario Ministry of Health and Long-Term Care. 2011. 〈www.health.gov.on.ca/english/providers/program/ohip/ sob/physserv/physserv-mn.html〉 (Accessed February 17, 2012).
29. Ontario Case Costing Initiative. Ontario case costing initiative website. Ontario Case Costing Initiative. 2011. 〈www.occp.com/〉 (Accessed February 20, 2012).
30. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin. Clin Infect Dis 2012;55(Suppl 2):S154-S161.
31. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84. (Pubitemid 41338761)
32. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007;44:238-44. (Pubitemid 46079988)
33. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: Patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010;50:194-201.
34. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703.
35. Cloud J, Noddin L, Pressman A, Hu M, Kelly C. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol 2009;7:868-73.
36. Martin H, Willey B, Low DE, et al. Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol 2008;46:2999-3004.
37. Johnson S. Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes. J Infect 2009;58:403-10.
38. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50.
39. Régie de l'assurance maladie du Québec. Liste de médicaments assurés. Régie de l'assurance maladie du Québec 2013 June 3;1-459. 〈www.ramq.gouv.qc.ca/fr/regie/lois/liste- med.shtml〉 (Accessed June 13, 2013).